EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[¹ÌºÐÈ­Á¶Á÷Çü Á¶±âÀ§¾ÏÀÇ ¸²ÇÁÀý ÀüÀÌ À§Çè. Risk of LN metastasis in EGCs with undifferentiated-type histology]

Áõ·Ê ÅäÀÇ. 2022-6-19. Live pig ESD hands-on training. ¿Ã¸²Çª½º ¼Ûµµ K-TEC training center


1. Ãʱ⠿¬±¸

1990³â´ëºÎÅÍ È®´ëÀûÀÀÁõÀ» ¾ð±ÞÇÑ ÀÛÀº ¿¬±¸µéÀÌ ÀÖ¾ú½À´Ï´Ù. ±×·¯³ª, È®´ëÀûÀÀÁõ¿¡ ´ëÇÑ ³íÀÇ°¡ º»°ÝÈ­ µÈ °ÍÀº À§¾ÏÀÌ ¸¹¾Ò´ø µÎ º´¿ø(µ¿°æ¾Ï¼¾ÅÍ¿Í µ¿°æ¾Ï¿¬±¸È¸º´¿ø)ÀÇ ¼ö¼ú ÈÄ ¸²ÇÁÀý ÀüÀÌ À§Çè ºÐ¼®À» ¹ÙÅÁÀ¸·Î ÇÑ 2000³â Dr. GotodaÀÇ Á¦¾È(Gastric Cancer 2010;3:219)ÀÌ °è±â°¡ µÇ¾ú½À´Ï´Ù. ¿©±â¿¡´Â undifferentiated-typeÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

2009³â µ¿°æ ¾Ï¿¬±¸È¸ º´¿øÀÇ Hirasawa´Â ¼ö¼úÀ» ¹ÞÀº undifferentiated-type Á¶±âÀ§¾ÏÀÇ º´¸®°á°ú¸¦ ºÐ¼®ÇÏ¿© 2000³â Gotoda ³í¹®ÀÇ °á°ú¸¦ ¹Ýº¹ÇÏ¿´½À´Ï´Ù. µÎ ¿¬±¸´Â µÎ °¡Áö Á¡¿¡¼­ ´Ù¸¨´Ï´Ù. (1) Gotoda´Â 3cm¸¦ Á¦½ÃÇÑ ¹Ý¸é, Hirasawa´Â 2cm¸¦ Á¦½ÃÇÏ¿´½À´Ï´Ù. ÀÌÈÄ ¸ðµç °¡À̵å¶óÀο¡¼­´Â 2cm°¡ Ç¥ÁØÀÌ µÇ¾ú½À´Ï´Ù. ¾î¶² data¸¦ ±âÁ¡À¸·Î 3cm°¡ 2cm·Î Á¼ÇôÁ³´ÂÁö´Â Àú´Â ¸ð¸£°Ú½À´Ï´Ù. (2) Hirasawa ¿¬±¸°¡ ´õ ÄDZ⠶§¹®¿¡ 95% confidence intervalÀÌ 0-0.96%·Î ´õ Á¼¾Ò½À´Ï´Ù. ÇÑ °¡Áö ¿ì·ÁÁ¡À» ¿¬±¸ ´ë»óÀÌ Áߺ¹µÈ °Í °°´Ù´Â °ÍÀÔ´Ï´Ù. µÑ ´Ù µ¿°æ¾Ï¿¬±¸È¸ º´¿ø°ú µ¿°æ¾Ï¼¾ÅÍÀÇ ÀڷḦ ¸ð¾Æ¼­ ºÐ¼®ÇÑ °ÍÀ̱⠶§¹®ÀÔ´Ï´Ù.


2011³â ¼­¿ï¾Æ»êº´¿øÀÇ ¿¬±¸(Chung JW. JGH. 2011)¿¡¼­´Â Á¡¸·¾ÏÀÇ ¸²ÇÁÀý ÀüÀÌ À§ÇèÀÌ ºÐ¼®µÇ¾ú½À´Ï´Ù. ÀúÀÚµéÀÌ Criteria III·Î ¸í¸íÇÑ 'undifferentiated less than 20 mm without ulceration'¿¡¼­´Â Åë°èÀûÀ» À¯ÀÇÇÑ ¼öÁØÀÇ ¸²ÇÁÀý ÀüÀÌ À§ÇèÀÌ ÀÖ´Â °ÍÀ¸·Î ºÐ¼®µÇ¾ú½À´Ï´Ù (1.15%, 3/261, 95% CI, 0-2.44%).


2012³â »ï¼º¼­¿ïº´¿øÀÇ ¿¬±¸(Lee JH. Br J Surg. 2012)¿¡¼­´Â poorly differentiated¸¸ µû·Î ºÐ¼®Çß½À´Ï´Ù. ESD ÀûÀÀÁõ°ú À¯»çÇÑ ±âÁØÀ» Àû¿ëÇÏ¿´´Âµ¥, À§ÇèÀÎÀÚ°¡ ¾ø´Â 124¸í Áß 4¸í (3.2%)¿¡¼­ ¸²ÇÁÀý ÀüÀÌ°¡ ÀÖ¾ú½À´Ï´Ù. ¿©·¯ ÀÚ·á¿¡¼­ singet ring cell Çüº¸´Ù P/D ÇüÀÌ ´õ À§ÇèÇÏ´Ù´Â Á¡À» ÁöÀûÇÑ °Í°ú °°Àº ¸Æ¶ôÀ̶ó°í »ý°¢µË´Ï´Ù.


2. ¿¬¼¼´ëÇб³ ½ÉÃæ³² ¼±»ý´ÔÀÇ ¸ÚÁø Á¾¼³ (2014)

2014³â ¿¬¼¼´ëÇб³ÀÇ ½ÉÃæ³² ¼±»ý´Ô²²¼­ undifferentiated-type EGCÀÇ ³»½Ã°æÄ¡·á¿¡ ´ëÇÑ Á¾¼³À» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù (Shim. World J Gastroenterol. 2014). ±âÁ¸¿¡ ¹ßÇ¥µÈ ¼ö¼úº´¸® °ËÅä °á°ú¸¦ Àß ¿ä¾àÇϼ̽À´Ï´Ù. ÀϺΠ¿¬±¸(ºÓÀº »ö µ¿±×¶ó¹Ì)¿¡¼­´Â 20m°¡ ¾Æ´Ï¶ó 10-15mm¸¦ ±âÁØÀ¸·Î Á¦½ÃÇÏ¿´´Ù´Â Á¡¿¡ ÁÖ¸ñÇϽñ⠹ٶø´Ï´Ù.

½ÉÃæ³² ¼±»ý´ÔÀº ³»½Ã°æÀ¸·Î Å©±â ÃøÁ¤ÀÇ ¿À·ù °¡´É¼ºÀ» Àß ¼³¸íÇϼ̽À´Ï´Ù. ½ÉÃæ³² ¼±»ý´Ô²²¼­´Â size discrepancy¿¡ ´ëÇÑ ³í¹®µµ ¹ßÇ¥ÇÑ ¹Ù ÀÖÀ¸¹Ç·Î (Shim. Surg Endosc. 2014), ÀÌ ºÎºÐ¿¡ °ü½ÉÀÌ ¸¹Àº °Í °°½À´Ï´Ù. ÇØ´ç ºÎºÐÀ» ¿Å±é´Ï´Ù (WJG 2014;20:3938-3949 Áß 3940ÂÊ).

Moreover, the size discrepancy between pathologic size and endoscopic size should be resolved, because we can only determine the indications of ER based on the endoscopically estimated size. While a previous study revealed that endoscopic visual estimation method was found to show reliable agreement with pathologic measurements in EGC treated with ER, other earlier ESD series showed the mean size discrepancies ranged from 5.8 mm to 6.8 mm, which are not negligible in ER for EGC. In UD-EGC, the margins of the lesion tend to be obscured compared to the differentiated histology, which was found to cause frequent margin failure of ESD in our previous report. Thus, a standard reliable measurement method is required through further prospective studies.

ºñ½ÁÇÑ ½Ã±â¿¡ ¿¬¼¼´ëÇб³¿¡¼­´Â signet ring cell carcinoma¿¡ ´ëÇÑ ESD¿¡¼­ Å©±âÀÇ ¿ªÇÒ¿¡ ´ëÇÏ¿© ºÐ¼®ÇÑ ¿¬±¸¸¦ ¹ßÇ¥ÇÏ°í ÀÖ½À´Ï´Ù (Kim MN. Dig Liver Dis. 2014). ÃÊ·ÏÀÇ Results ºÎºÐÀÌ ¾ÆÁÖ ¸í·áÇÏ°Ô Àß Á¤¸®µÇ¾î À־ ¼ýÀÚ¸¦ »©°í ¿Å±é´Ï´Ù.

Multivariate analysis showed that large tumour size was the only significant factor related to incomplete resection. In addition, large tumour size was the only significant factor related to endoscopic size underestimation. The rate of endoscopic size underestimation was significantly higher in tumours with a size ¡Ã20mm.


3. Á¡¸·¿¡ ±¹ÇÑµÈ signet ring cell carcinomaÀÇ ¸²ÇÁÀý ÀüÀÌ À§Çè

2016³â 1¿ù Ann Surg¿¡ Á¡¸·¿¡ ±¹ÇÑµÈ signet ring cell carcinomaÀÇ ¸²ÇÁÀý ÀüÀÌ À§Çè¿¡ ´ëÇÑ »ï¼º¼­¿ïº´¿øÀÇ ºÐ¼®ÀÌ ¹ßÇ¥µÇ¾ú½À´Ï´Ù (Pyo JH. Ann Surg 2016). 1,544¸íÀÇ È¯ÀÚ¸¦ ºÐ¼®ÇÏ¿´À» ¶§ ¸²ÇÁÀý ÀüÀÌ´Â 3.8%¿¡¼­ ¹ß°ßµÇ¾ú½À´Ï´Ù.

¼¼ °³ÀÇ À§ÇèÀÎÀÚ°¡ È®ÀεǾú½À´Ï´Ù ((tumor size ¡Ã1.7 cm, tumors of elevated type, and lymphatic-vascular involvement). Non-elevated type¿¡ ºñÇÏ¿© elevated typeÀÌ ¹«·Á 5¹è À§ÇèÇß½À´Ï´Ù.

¼¼ À§ÇèÀÎÀÚ¸¦ ÀÌ¿ëÇÏ¿© risk scoring systemÀÌ ¸¸µé¾îÁ³°í À̸¦ Àû¿ëÇÏ¿´À» ¶§ÀÇ Á¡¼ö¿Í ¸²ÇÁÀý ÀüÀÌ°¡ linearÇÑ °ü°è°¡ ÀÖÀ½À» º¸¿©ÁÖ¾ú½À´Ï´Ù.


[References]

1) Á¶±âÀ§¾Ï ¸²ÇÁÀý ÀüÀÌ À§ÇèÀÎÀÚ



© EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà